BPC-157 (Body Protection Compound) caps

• 1 × 500 mcg (30 capsules) capsules presentation
• Active listing: BPC-157 (Body Protection Compound) caps
• Total API (label): 15 mg
• SKU PV-BPC-157-BODY-PROTECTION-COMP-500MCG30CAPSULES
• Oral capsule bottle — store per label away from moisture
• PureVital professional clinical formulary supply

Preclinical and translational literature has explored BPC-157 across tendon, ligament, muscle, gastrointestinal mucosa, and wound-healing models. Clinics value clear presentation labeling (mg/mL or mcg/capsule) so protocols stay reproducible.

• Studied for tendon, ligament, and muscle recovery biology
• Explored for GI mucosal protection in experimental models
• Discussed for angiogenesis and localized tissue repair support

• Angiogenesis pathways (including VEGF-related signaling discussed in literature)
• Nitric oxide / eNOS modulation linked to vascular tone and healing milieu
• Anti-inflammatory cytokine modulation (e.g., TNF-α, IL-6 signals in models)
• Support for fibroblast activity, collagen organization, and tendon cell behavior
• Neuroprotective signaling explored in CNS injury models

Injectable programs often use gradual subcutaneous titration. Literature-style reference ranges discussed by research clinics include starting near 250 mcg daily and stepping toward higher daily amounts as tolerated — always recalculated to your vial’s mg/mL concentration. Capsule programs use fixed mcg strengths (e.g., 500 mcg) on schedules set by the prescribing clinician.

• Prefer subcutaneous administration for injectable SKUs unless your protocol states otherwise
• Rotate injection sites; avoid intravascular administration
• Align daily volume to labeled concentration (example: 5 mg/mL implies 0.05 mL ≈ 250 mcg)
• Cycle length and 5- vs 7-day schedules are clinician-defined

Clinic note: Reference themes only — not a patient-facing prescription.

• Accelerated soft-tissue healing signals in tendon/ligament/muscle models
• GI mucosa protection themes in gastritis / barrier models
• Enhanced microcirculation discussion in damaged tissue models
• Neuroprotective findings in select trauma models
• Reduction of inflammatory markers in experimental settings

Available reports generally describe a favorable tolerability profile with mostly mild, uncommon effects.

• Injection-site irritation or redness
• Mild headache or dizziness (uncommon)
• Transient fatigue in sensitive individuals
• No major systemic toxicity pattern widely established in available summaries

• Hypersensitivity to peptide formulations or excipients
• Injectable SKUs: subcutaneous use only — do not inject IV/IM unless protocol expressly differs
• Use caution with active bleeding disorders or anticoagulant therapy (angiogenic biology)
• Avoid unsupervised combinations with systemic corticosteroids

• No robust catalog of negative drug–drug interactions published to date
• Theoretical synergy discussions with GH secretagogues (e.g., Ipamorelin) and gut-supportive agents
• Still review the full medication list in clinic before combining peptides

Human data in pregnancy and lactation are insufficient; avoid use unless a specialist explicitly directs otherwise. Pediatric safety and efficacy are not established.

BPC-157 is not FDA-approved as a finished pharmaceutical drug for general therapeutic marketing. It is discussed as an investigational / compounding-context peptide. Clinics must follow applicable laws for possession, compounding, and dispensing.

• Sikiric P, et al. — BPC-157 and healing of muscle, tendon, ligament, and bone (orthopaedic research literature)
• Brcic L, et al. — Inflammatory pathway modulation by BPC-157
• Seiwerth S, et al. — Cytoprotective peptide perspectives on BPC-157
• Drmic D, et al. — Wound healing and tissue repair acceleration themes
• Reviews on peptides in regenerative medicine (2020s literature)